Spectral AI Raises up to $15 Million of Debt Financing and Strengthens Financial Position for U.S. Commercialization
Spectral AI (NASDAQ: MDAI) has secured up to $15 million in debt financing from Avenue Venture Opportunities Fund II, with an initial draw of $8.5 million. The company also raised $2.7 million in equity financing from institutional and existing investors.
The financing agreement spans three years with an interest-only payment period of 15-24 months, depending on milestone achievement. A second financing tranche, contingent on FDA clearance of the DeepView System, includes an additional $6.5 million in debt and a $7.0 million equity raise.
The deal includes warrant coverage of 8.5% with an exercise price of $1.80 per share, and a six-month market standstill period. With total cash now exceeding $14 million, Spectral AI aims to accelerate the U.S. commercialization of its AI-driven DeepView System, designed to predict burn healing potential using multi-spectral imaging and AI algorithms.
Spectral AI (NASDAQ: MDAI) ha ottenuto fino a 15 milioni di dollari in finanziamenti tramite debito dal fondo Avenue Venture Opportunities Fund II, con un primo prelievo di 8,5 milioni di dollari. L'azienda ha anche raccolto 2,7 milioni di dollari in finanziamenti azionari da investitori istituzionali e già esistenti.
L'accordo di finanziamento si estende su tre anni con un periodo di pagamento solo per interessi di 15-24 mesi, a seconda del raggiungimento dei traguardi. Una seconda tranche di finanziamento, subordinata all'approvazione della FDA per il DeepView System, include ulteriori 6,5 milioni di dollari in debito e una raccolta di 7,0 milioni di dollari in equity.
L'accordo prevede una copertura di warrant dell'8,5% con un prezzo di esercizio di 1,80 dollari per azione e un periodo di standstill di mercato di sei mesi. Con un totale di liquidità ora superiore a 14 milioni di dollari, Spectral AI punta ad accelerare la commercializzazione negli Stati Uniti del suo sistema DeepView, guidato dall'IA, progettato per prevedere il potenziale di guarigione delle ustioni utilizzando immagini multispettrali e algoritmi di intelligenza artificiale.
Spectral AI (NASDAQ: MDAI) ha asegurado hasta 15 millones de dólares en financiamiento de deuda del Avenue Venture Opportunities Fund II, con un primer desembolso de 8,5 millones de dólares. La compañía también recaudó 2,7 millones de dólares en financiamiento de capital de inversores institucionales y existentes.
El acuerdo de financiamiento abarca tres años con un período de pago solo de intereses de 15 a 24 meses, dependiendo del logro de hitos. Una segunda tranche de financiamiento, sujeta a la aprobación de la FDA del DeepView System, incluye 6,5 millones de dólares adicionales en deuda y una recaudación de capital de 7,0 millones de dólares.
El acuerdo incluye cobertura de warrants del 8,5% con un precio de ejercicio de 1,80 dólares por acción, y un período de standstill de mercado de seis meses. Con un total de efectivo ahora superior a 14 millones de dólares, Spectral AI busca acelerar la comercialización en EE. UU. de su sistema DeepView, impulsado por IA, diseñado para predecir el potencial de curación de quemaduras utilizando imágenes multispectrales y algoritmos de IA.
스펙트럴 AI (NASDAQ: MDAI)는 애비뉴 벤처 기회 펀드 II로부터 최대 1,500만 달러의 부채 자금을 확보했으며, 초기 인출액은 850만 달러입니다. 이 회사는 또한 기관 투자자와 기존 투자자로부터 270만 달러의 자본 조달을 했습니다.
금융 계약은 3년에 걸쳐 있으며, 이자만 지급하는 기간은 이정표 달성에 따라 15-24개월입니다. FDA의 DeepView System 승인에 따라 조건부인 두 번째 자금 조달에서는 추가로 650만 달러의 부채와 700만 달러의 자본 조달이 포함됩니다.
이번 거래에는 8.5%의 워런트 커버리지와 주당 1.80달러의 행사 가격이 포함되며, 6개월의 시장 정지 기간이 있습니다. 현재 현금 총액이 1,400만 달러를 초과함에 따라 스펙트럴 AI는 다중 스펙트럼 이미징 및 AI 알고리즘을 사용하여 화상 치유 가능성을 예측하도록 설계된 AI 기반 DeepView 시스템의 미국 상용화를 가속화할 계획입니다.
Spectral AI (NASDAQ: MDAI) a sécurisé jusqu'à 15 millions de dollars de financement par emprunt auprès du fonds Avenue Venture Opportunities Fund II, avec un premier tirage de 8,5 millions de dollars. L'entreprise a également levé 2,7 millions de dollars en financement par actions auprès d'investisseurs institutionnels et existants.
Le contrat de financement s'étend sur trois ans avec une période de paiement d'intérêts uniquement de 15 à 24 mois, en fonction de l'atteinte des jalons. Une deuxième tranche de financement, conditionnée à l'approbation de la FDA pour le DeepView System, comprend 6,5 millions de dollars supplémentaires en dette et une levée de fonds de 7,0 millions de dollars.
L'accord comprend une couverture de warrants de 8,5 % avec un prix d'exercice de 1,80 dollar par action, et une période de gel de six mois sur le marché. Avec un total de liquidités maintenant supérieur à 14 millions de dollars, Spectral AI vise à accélérer la commercialisation aux États-Unis de son système DeepView, alimenté par l'IA, conçu pour prédire le potentiel de guérison des brûlures en utilisant l'imagerie multispectrale et des algorithmes d'IA.
Spectral AI (NASDAQ: MDAI) hat bis zu 15 Millionen Dollar an Fremdkapitalfinanzierung vom Avenue Venture Opportunities Fund II gesichert, mit einer ersten Auszahlung von 8,5 Millionen Dollar. Das Unternehmen hat außerdem 2,7 Millionen Dollar an Eigenkapitalfinanzierung von institutionellen und bestehenden Investoren gesammelt.
Die Finanzierungsvereinbarung erstreckt sich über drei Jahre mit einer nur Zinszahlungsperiode von 15-24 Monaten, abhängig vom Erreichen von Meilensteinen. Eine zweite Finanzierungsrunde, die von der Genehmigung der FDA für das DeepView System abhängig ist, umfasst zusätzliche 6,5 Millionen Dollar an Schulden und eine Eigenkapitalerhöhung von 7,0 Millionen Dollar.
Der Deal beinhaltet eine Warrants-Abdeckung von 8,5% mit einem Ausübungspreis von 1,80 Dollar pro Aktie und einer sechsmonatigen Marktstillhalteperiode. Mit einem Gesamtkapital von nunmehr über 14 Millionen Dollar strebt Spectral AI an, die Kommerzialisierung seines KI-gesteuerten DeepView Systems in den USA zu beschleunigen, das darauf ausgelegt ist, das Heilungspotenzial von Verbrennungen mithilfe von multispektraler Bildgebung und KI-Algorithmen vorherzusagen.
- Secured substantial funding with $8.5M initial debt draw and $2.7M equity financing
- Strong cash position of over $14M to support commercialization
- Potential access to additional $6.5M in debt financing
- 15-24 month interest-only payment period provides financial flexibility
- Six-month market standstill prevents dilutive stock sales
- Additional equity raise of $7M required for second tranche
- Warrant coverage of 8.5% may lead to future dilution
- FDA clearance required to access second financing tranche
- Takes on debt obligations with interest payments
Insights
Spectral AI's $15M debt financing package represents a significant capital infusion for a company with just
The initial
The financing terms are particularly favorable - a 15-month interest-only period (extendable to 24 months) minimizes near-term cash outflows during the critical commercial launch phase. The 6-month market standstill prevents dilutive financing activities, protecting current shareholders.
Most compelling is the second tranche structure - tying
Avenue Capital's participation brings institutional validation beyond just capital. For a company at this pivotal pre-commercialization stage, removing financing uncertainty allows management to focus exclusively on product launch execution - precisely what's needed to maximize shareholder value.
Spectral AI's DeepView System represents a potentially transformative approach to burn wound assessment. The system combines multi-spectral imaging with AI algorithms to objectively predict healing potential - addressing a critical clinical challenge that has historically relied on subjective visual assessment.
This financing package is strategically timed to support U.S. commercialization efforts, suggesting the company is in final preparation stages for market entry. The staged financing approach with the second tranche contingent on FDA clearance creates a milestone-based capital structure that rewards regulatory success.
For burn care specialists, the DeepView technology could significantly impact treatment decisions by providing objective healing prediction. Early and accurate identification of wounds requiring surgical intervention versus those that will heal naturally could reduce unnecessary procedures, improve resource allocation, and potentially enhance patient outcomes.
Avenue Capital's statement highlighting the impressive clinical data suggests the technology has demonstrated compelling evidence of efficacy. The comment from their Senior Portfolio Manager that the system "will offer significant benefits to burn victims" indicates confidence in both regulatory approval and clinical adoption.
This financing positions Spectral AI to execute a comprehensive commercialization strategy - essential for successful medical technology market penetration, particularly for novel AI-driven diagnostic platforms in established clinical workflows.
DALLAS, March 24, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ: MDAI) ("Spectral AI" or the "Company"), a leading developer of the AI-driven DeepView® System, which uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced the successful completion of a debt financing agreement of up to
The term of the financing agreement is for three years, with an interest-only payment period of no less than 15 months, which can be extended to 24 months upon achieving the milestones laid out in the second financing tranche. The second financing tranche, which is contingent upon FDA clearance of the DeepView System, includes an additional
“This significant financing provides Spectral AI with the resources necessary to finalize our commercialization efforts and bring our cutting-edge DeepView System across the finish line to the U.S. market,” said Dr. J. Michael DiMaio, M.D., Chairman of the Board of Directors of Spectral AI. “We are excited to be working with Avenue Capital and expect the partnership to provide long-term benefits to the Company. This supports our efforts to bring our technology to market and transform the way healthcare providers predict burn wound healing potential and ultimately improve patient outcomes.”
“We have been impressed with the clinical data generated by Spectral AI’s DeepView System and we believe it will offer significant benefits to burn victims in the future,” said Chad Norman, Senior Portfolio Manager at Avenue Capital Group.
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. The DeepView® System is being developed as a predictive device to offer clinicians an objective and immediate assessment of a burn wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, the DeepView® System is expected to provide fast and accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about the DeepView® System, visit www.spectral-ai.com.
Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
For Media and Investor Relations, please contact:
David Kugelman
Atlanta Capital Partners LLC
(866) 692-6847 Toll Free - U.S. & Canada
(404) 281-8556 Mobile and WhatsApp
Email: dk@atlcp.com
FAQ
How much total financing did Spectral AI (MDAI) secure in March 2024?
What are the terms of MDAI's debt financing agreement?
What conditions must MDAI meet for the second financing tranche?
What is the purpose of Spectral AI's DeepView System?
